WMS Berlin continues to deliver evolving data and novel insights into the treatment, study and diagnosis of Duchenne Muscular Dystrophy. The location in one of the historical districts for Berlin […]
CureDuchenne is delighted to share the news that Prosensa announced today that it has begun the submission process for a New Drug Application filing to the FDA for its lead […]
The world’s leading experts in the neuromuscular field have gathered in Berlin this week for the World Muscle Society meeting. The focus of the 19th Annual Congress of the World […]
The main objective of this study is to provide confirmatory evidence of efficacy of eteplirsen (AVI-4658) in Duchenne muscular dystrophy (DMD) patients that are amenable to skipping exon 51. Additional objectives include evaluation of safety and biomarkers.
79 Days…79 Videos…More than 79 talented individuals A sincere and heartfelt thank you to Sarah Burgess for her talent, creativity and inspiration in creating the 79 Days of Duchenne […]
Prosensa Holding N.V. (NASDAQ: RNA), the biopharmaceutical company focusing on RNA-modulating therapeutics for rare diseases with high unmet need, today announced that the results of its research into developing an accurate and reproducible method for the measurement of dystrophin in patients with Duchenne muscular dystrophy (DMD) and Becker’s muscular dystrophy (BMD) have been published in the online peer reviewed journal PLOS ONE (https://bit.ly/ZJ8ShM).
CureDuchenne is proud to have supported all types of Duchenne research over the past 10 years. That is why CureDuchenne has been a leader in funding exon skipping, stop codon, […]
UPPMD is hosting a Prosensa Update About Drisapersen & Other Programs webinar on behalf of all of its member organizations worldwide. Date and Time: Thursday October 2nd 2014 at 6pm CET […]
CureDuchenne is delighted to share that Prosensa has begun re-dosing patients. See below for today’s announcement. We are happy that CureDuchenne funding is helping to move Prosensa’s exon skipping programs forward. […]
